BE, N., S, S., S, D., N, S., S, P., JA, M., . . . F, M. (2023). Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer. Cancer, 129(14), 2201. https://doi.org/10.1002/cncr.34773
Chicago Style (17th ed.) CitationBE, Nelson, et al. "Phase 1b Study of Combined Selinexor and Eribulin for the Treatment of Advanced Solid Tumors and Triple-negative Breast Cancer." Cancer 129, no. 14 (2023): 2201. https://doi.org/10.1002/cncr.34773.
MLA (9th ed.) CitationBE, Nelson, et al. "Phase 1b Study of Combined Selinexor and Eribulin for the Treatment of Advanced Solid Tumors and Triple-negative Breast Cancer." Cancer, vol. 129, no. 14, 2023, p. 2201, https://doi.org/10.1002/cncr.34773.
Warning: These citations may not always be 100% accurate.
